Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma
Miriam Ficial(Barts Health NHS Trust), Sabina Signoretti(Brigham and Women's Hospital), Miriam Sant’Angelo(Brigham and Women's Hospital), Jean‐Christophe Pignon(Brigham and Women's Hospital), Yue Hou(Inner Mongolia Medical University), Arlene H. Sharpe(Brigham and Women's Hospital), Catherine J. Wu(Dana-Farber Cancer Institute), Toni K. Choueiri(Harvard University), Michael B. Atkins(Georgetown University), Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Abdallah Flaifel(Brigham and Women's Hospital), Paul J. Catalano(Computational Physics (United States)), David A. Braun(Yale Cancer Center), Gordon J. Freeman(Dana-Farber Cancer Institute), Sachet A. Shukla(Broad Institute), F. Stephen Hodi(Harvard University), Opeyemi A. Jegede(Dana-Farber Cancer Institute), David F. McDermott(Beth Israel Deaconess Medical Center), Megan Wind‐Rotolo(Bristol-Myers Squibb (United States)), Maura Sticco-Ivins(Brigham and Women's Hospital)
Cited by 81
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
The Immune Landscape of Cancer
|Immunity|2018|6.2k
PD-1 and Its Ligands in Tolerance and Immunity
|Annual Review of Immunology|2008|5.3k
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k